Cellectar's Iopofosine I 131 Delivers Durable Responses in Tough-to-Treat Waldenström Macroglobulinemia: 83.6% Response Rate Achieved
Market Chameleon (Tue, 5-May 9:53 AM)
Cellectar Biosciences Delivers Durable, High-Quality Responses in Refractory Waldenström’s Macroglobulinemia: 12-Month CLOVER WaM Data Strengthens Accelerated Approval Outlook
Market Chameleon (Tue, 5-May 7:34 AM)
